Xeris Biopharma Holdings, Inc.
XERS
$7.59
$0.020.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 46.28% | 30.01% | 11.92% | -2.13% | 16.62% |
| Total Depreciation and Amortization | -3.23% | -4.84% | -4.07% | -4.87% | -1.02% |
| Total Amortization of Deferred Charges | 32.81% | 47.00% | 36.37% | 27.47% | 24.34% |
| Total Other Non-Cash Items | 78.48% | 155.30% | 79.24% | 184.06% | 1,009.98% |
| Change in Net Operating Assets | -514.79% | -743.60% | -40.13% | 134.18% | 85.79% |
| Cash from Operations | 57.19% | 35.15% | 21.36% | 55.41% | 48.76% |
| Capital Expenditure | 42.29% | 67.25% | 61.64% | 65.53% | 50.43% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 30.44% | 23.02% | 253.73% | 211.38% | 188.37% |
| Cash from Investing | 35.66% | 33.81% | 181.33% | 183.18% | 173.67% |
| Total Debt Issued | -100.00% | -100.00% | -- | 2.21% | 2.21% |
| Total Debt Repaid | 200.00% | -- | -- | -- | -- |
| Issuance of Common Stock | 518.22% | 489.90% | 198.28% | 30.03% | 30.03% |
| Repurchase of Common Stock | -152.55% | -131.79% | -270.07% | -268.71% | -284.85% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -898.40% | 100.00% | -898.40% | -21,593.33% | -441.10% |
| Cash from Financing | -105.44% | -106.28% | 2,342.28% | -29.20% | -29.01% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -85.94% | -137.57% | 107.45% | 138.12% | 125.11% |